Zacks: Analysts Expect Medpace Holdings, Inc. (NASDAQ:MEDP) Will Announce Quarterly Sales of $309.20 Million

Analysts expect Medpace Holdings, Inc. (NASDAQ:MEDP) to post $309.20 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Medpace’s earnings. The highest sales estimate is $310.90 million and the lowest is $306.40 million. Medpace posted sales of $259.68 million during the same quarter last year, which suggests a positive year over year growth rate of 19.1%. The company is expected to issue its next quarterly earnings results on Monday, February 21st.

According to Zacks, analysts expect that Medpace will report full-year sales of $1.14 billion for the current year. For the next fiscal year, analysts expect that the firm will report sales of $1.44 billion, with estimates ranging from $1.43 billion to $1.45 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Medpace.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Sunday, October 24th. The company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.07 by $0.22. Medpace had a net margin of 16.71% and a return on equity of 21.71%. The business had revenue of $295.57 million for the quarter, compared to analysts’ expectations of $291.55 million. During the same quarter last year, the company posted $1.13 earnings per share. The company’s quarterly revenue was up 28.3% compared to the same quarter last year.

Separately, Zacks Investment Research raised shares of Medpace from a “hold” rating to a “buy” rating and set a $239.00 target price on the stock in a report on Thursday, October 28th.

NASDAQ MEDP traded up $1.39 during trading hours on Thursday, reaching $214.01. The company’s stock had a trading volume of 115,783 shares, compared to its average volume of 183,377. The business has a 50-day simple moving average of $203.93 and a 200 day simple moving average of $187.45. Medpace has a 52 week low of $121.52 and a 52 week high of $231.00. The stock has a market cap of $7.69 billion, a PE ratio of 44.22 and a beta of 1.33.

In other Medpace news, Director Ashley M. Keating sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 26th. The shares were sold at an average price of $210.00, for a total value of $420,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 12,675 shares of the firm’s stock in a transaction that occurred on Tuesday, August 31st. The shares were sold at an average price of $182.04, for a total transaction of $2,307,357.00. Following the transaction, the chief executive officer now owns 706,643 shares in the company, valued at approximately $128,637,291.72. The disclosure for this sale can be found here. Insiders sold 40,405 shares of company stock worth $7,806,361 in the last 90 days. 22.00% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of MEDP. Marshall Wace LLP bought a new stake in Medpace during the first quarter worth approximately $99,000. FMR LLC boosted its holdings in Medpace by 6,709.3% during the first quarter. FMR LLC now owns 37,247 shares of the company’s stock worth $2,196,000 after buying an additional 36,700 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in Medpace by 1.4% during the first quarter. Thrivent Financial for Lutherans now owns 7,315 shares of the company’s stock worth $1,200,000 after buying an additional 104 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in Medpace by 21.3% during the first quarter. Nuveen Asset Management LLC now owns 189,924 shares of the company’s stock worth $31,157,000 after buying an additional 33,344 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in Medpace by 49.3% during the first quarter. Janus Henderson Group PLC now owns 44,710 shares of the company’s stock worth $7,335,000 after buying an additional 14,772 shares in the last quarter. Hedge funds and other institutional investors own 96.20% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Recommended Story: How to calculate the annual rate of depreciation

Get a free copy of the Zacks research report on Medpace (MEDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.